The Administrative Core is responsible for providing administrative and organizational support for the leadership of the Mayo Clinic Breast Cancer SPORE in order to ensure optimal function of all SPORE components, and communications between the SPORE, Mayo Clinic Cancer Center, Mayo Clinic as a whole, other breast SPOREs, other Mayo SPOREs, SPORE collaborations with non-SPORE funding Instruments, and the National Cancer Institute. An important responsibility ofthe Administrative Core is to support the activities of the Breast SPORE Advocacy Advisory Committee and, in particular, facilitate the integration of the project-specific advocates into the activities of their respective projects. This Core is crucial to the optimal integration of all SPORE activities that are necessary for effective and efficient oversight. The Administrative Core will coordinate the activities of the SPORE Executive Committee, the SPORE Advocacy Advisory Committee, the Mayo Inter-SPORE Advisory Committee, the SPORE Internal Scientific Advisory Committee, the SPORE External Advisory Board, and the Breast SPORE Operations Committee. All ofthe committees have specific functions focusing on maximizing the translational research productivity. This Core will also provide administrative support for the activities of the Developmental Research Program and the Career Development Program. The Administrative Core will assist the SPORE Director in coordinating and facilitating the Research Projects and ensuring the proper functioning ofthe Cores in support of the translational research efforts. This Core will coordinate the monthly SPORE scientific meetings, the monthly Key Personnel meetings, the Breast SPORE involvement in the annual Mayo InterSPORE Retreat, and the participation of Breast SPORE investigators in the Annual Translational Science Meeting in Washington, DC. The Core will provide administrative assistance to the SPORE Director in terms of oversight of all SPORE activities including the research projects, functioning ofthe Biospecimen and Pathology Core and the Biostatistics and Patients Registry Core, the Developmental Research Program, the Career Development Program, and all fiscal matters. The Administrative Core will assist the SPORE Director in preparation of all annual Progress Reports to NCI, the competitive renewal application, and all other reports related to the SPORE award.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA116201-08
Application #
8744909
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (M1))
Project Start
2013-09-01
Project End
2016-08-31
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
8
Fiscal Year
2013
Total Cost
$114,194
Indirect Cost
$37,080
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Leontovich, Alexey A; Jalalirad, Mohammad; Salisbury, Jeffrey L et al. (2018) NOTCH3 expression is linked to breast cancer seeding and distant metastasis. Breast Cancer Res 20:105
Kurmi, Kiran; Hitosugi, Sadae; Yu, Jia et al. (2018) Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metab 28:833-847.e8
Augusto, Bianca; Kasting, Monica L; Couch, Fergus J et al. (2018) Current Approaches to Cancer Genetic Counseling Services for Spanish-Speaking Patients. J Immigr Minor Health :
Supekar, Nitin T; Lakshminarayanan, Vani; Capicciotti, Chantelle J et al. (2018) Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide. Chembiochem 19:121-125
Rebbeck, Timothy R (see original citation for additional authors) (2018) Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 39:593-620
Msaouel, Pavlos; Opyrchal, Mateusz; Dispenzieri, Angela et al. (2018) Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects. Curr Cancer Drug Targets 18:177-187
Fasching, Peter A; Loibl, Sibylle; Hu, Chunling et al. (2018) BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. J Clin Oncol 36:2281-2287
Rice, Megan S; Tamimi, Rulla M; Bertrand, Kimberly A et al. (2018) Does mammographic density mediate risk factor associations with breast cancer? An analysis by tumor characteristics. Breast Cancer Res Treat 170:129-141
Wang, Liewei; Ingle, James; Weinshilboum, Richard (2018) Pharmacogenomic Discovery to Function and Mechanism: Breast Cancer as a Case Study. Clin Pharmacol Ther 103:243-252
Augusto, Bianca M; Lake, Paige; Scherr, Courtney L et al. (2018) From the laboratory to the clinic: sharing BRCA VUS reclassification tools with practicing genetics professionals. J Community Genet 9:209-215

Showing the most recent 10 out of 473 publications